Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinmaitong is a traditional Chinese medicine (TCM) multi-herbal formula used primarily for cardiovascular and metabolic diseases. It is commonly prescribed for conditions such as coronary heart disease, hypertension, stroke, and type 2 diabetes mellitus. The formulation contains several medicinal botanicals including Angelica sinensis, Salvia miltiorrhiza, Ilex pubescens, and Pueraria lobata. Pharmacological studies indicate that Xinmaitong promotes blood circulation, clears blood stasis, nourishes the heart, lowers blood lipid levels, and regulates blood pressure. Recent research has shown that its anti-diabetic effects are mediated by upregulating glucagon-like peptide-1 receptor (GLP-1R) expression in pancreatic β-cells—enhancing insulin secretion via cAMP signaling and Ca²⁺ influx pathways. Identified active components include morin, ginsenoside F1 (from Panax species), cynaroside, eriodictyol, rhapontin, narcissoside and ononin[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinmaitong.